{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T06:01:35Z","timestamp":1769148095778,"version":"3.49.0"},"reference-count":104,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2019,5,25]],"date-time":"2019-05-25T00:00:00Z","timestamp":1558742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>In the last few years, substantial progress has been made in the treatment of ovarian cancer, with increased knowledge about the biology of the disease. Ovarian cancer is a neoplasm strongly linked to defects in DNA repair mechanisms, where deficiency in the homologous recombination (HR) system results in a better response of ovarian cancers to therapy, whether platinum-based chemotherapy, anthracyclines, or poly (ADP-ribose) polymerase (PARP) inhibitors. More recently, it has been demonstrated that different ovarian cancer histotypes may have different immunogenicity. Interestingly, defects in HR systems are associated more frequently with higher tumor infiltrating lymphocytes, providing a rationale for developing combination therapy with immune-modulating agents and PARP inhibitors. Again, locoregional therapies combining heat shock and chemotherapy delivery have been shown to induce an anticancer immune response in vitro. Thus, the potential for locoregional therapeutic approaches that may impact the immune system, perhaps in combination with immune-modulating agents or PARP inhibitors, needs to be further explored. With this premise, we reviewed the main biological and clinical data demonstrating a strict interplay between the immune system, DNA repair mechanisms, and intraperitoneal therapies in ovarian cancer, with a focus on potential future therapeutic implications.<\/jats:p>","DOI":"10.3390\/ijms20102569","type":"journal-article","created":{"date-parts":[[2019,5,26]],"date-time":"2019-05-26T23:07:27Z","timestamp":1558912047000},"page":"2569","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Immune System and DNA Repair Defects in Ovarian Cancer: Implications for Locoregional Approaches"],"prefix":"10.3390","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3289-8041","authenticated-orcid":false,"given":"Alberto","family":"Farolfi","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola 47014, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4036-5568","authenticated-orcid":false,"given":"Giorgia","family":"Gurioli","sequence":"additional","affiliation":[{"name":"Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola 47014, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Fugazzola","sequence":"additional","affiliation":[{"name":"General and Emergency Surgery, Maurizio Bufalini Hospital, Cesena 47521, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Burgio","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola 47014, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Casanova","sequence":"additional","affiliation":[{"name":"Oncology Department, Santa Maria delle Croci Hospital, Ravenna 48121, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgia","family":"Ravaglia","sequence":"additional","affiliation":[{"name":"Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola 47014, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1598-9451","authenticated-orcid":false,"given":"Amelia","family":"Altavilla","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola 47014, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Costantini","sequence":"additional","affiliation":[{"name":"Pathology Unity, Morgagni-Pierantoni Hospital, Forl\u00ec 47121, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Amadori","sequence":"additional","affiliation":[{"name":"Department of Gynecological, Morgagni-Pierantoni Hospital, Forl\u00ec 47121, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Framarini","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Morgagni-Pierantoni Hospital, Forl\u00ec 47121, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Ansaloni","sequence":"additional","affiliation":[{"name":"General and Emergency Surgery, Maurizio Bufalini Hospital, Cesena 47521, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7520-2908","authenticated-orcid":false,"given":"Ugo","family":"De Giorgi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola 47014, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2019,5,25]]},"reference":[{"key":"ref_1","unstructured":"(2019, April 18). GLOBOCAN. Available online: http:\/\/gco.iarc.fr\/."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.humpath.2018.06.018","article-title":"Ovarian carcinomas: At least five different diseases with distinct histological features and molecular genetics","volume":"80","author":"Prat","year":"2018","journal-title":"Hum. Pathol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/PAT.0b013e328348a6e7","article-title":"Morphological subtypes of ovarian carcinoma: A review with emphasis on new developments and pathogenesis","volume":"43","author":"McCluggage","year":"2011","journal-title":"Pathology"},{"key":"ref_6","unstructured":"Kurman, R.J., Carcangiu, M.L., Herrington, C.S., and Young, R.H. (2014). WHO classification of tumours of female reproductive organs, 4th ed, International Agency for Research on Cancer."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3802\/jgo.2013.24.2.160","article-title":"Comparison of advanced stage mucinous epithelial ovarian cancer and serous epithelial ovarian cancer with regard to chemosensitivity and survival outcome: A matched case-control study","volume":"24","author":"Karabuk","year":"2013","journal-title":"J. Gynecol. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/jnci\/djj465","article-title":"Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: A kin-cohort study in Ontario, Canada","volume":"98","author":"Risch","year":"2006","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.tig.2014.06.003","article-title":"Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches","volume":"30","author":"Dietlein","year":"2014","journal-title":"Trends Genet."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Press, J.Z., De Luca, A., Boyd, N., Young, S., Troussard, A., Ridge, Y., Kaurah, P., Kalloger, S.E., Blood, K.A., and Smith, M. (2008). Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer, 8.","DOI":"10.1186\/1471-2407-8-17"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1200\/JCO.2009.27.2997","article-title":"Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer","volume":"28","author":"Hennessy","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network (2011). Integrated Genomic Analyses Of Ovarian Carcinoma. Nature, 474, 609\u2013615.","DOI":"10.1038\/nature10166"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1093\/jnci\/94.18.1396","article-title":"Inactivation of BRCA1 and BRCA2 in ovarian cancer","volume":"94","author":"Hilton","year":"2002","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/jnci\/94.1.61","article-title":"Frequency of BRCA1 dysfunction in ovarian cancer","volume":"94","author":"Geisler","year":"2002","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1471-0528.2010.02838.x","article-title":"PARP inhibitors and epithelial ovarian cancer: An approach to targeted chemotherapy and personalised medicine","volume":"118","author":"Mukhopadhyay","year":"2011","journal-title":"Br. J. Obstet. Gynaecol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/PAS.0b013e31823bc434","article-title":"Ovarian endometrioid adenocarcinoma: Incidence and clinical significance of the morphologic and immunohistochemical markers of mismatch repair protein defects and tumor microsatellite instability","volume":"36","author":"Aysal","year":"2012","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1056\/NEJMra1813254","article-title":"Mucinous Ovarian Carcinoma","volume":"380","author":"Morice","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer","volume":"378","author":"Koole","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1245\/s10434-014-4157-9","article-title":"Cytoreductive surgery and HIPEC in recurrent epithelial ovariancancer: A prospective randomized phase III study","volume":"22","author":"Spiliotis","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/ijc.29011","article-title":"HIPEC ROC I: A phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer","volume":"136","author":"Zivanovic","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0921-8777(00)00046-X","article-title":"Going APE over ref-1","volume":"461","author":"Evans","year":"2000","journal-title":"Mutat. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1128\/MCB.00030-16","article-title":"Base Excision Repair, a Pathway Regulated by Posttranslational Modifications","volume":"36","author":"Carter","year":"2016","journal-title":"Mol. Cell. Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5878","DOI":"10.1158\/1078-0432.CCR-12-1380","article-title":"Functional, genetic, and epigenetic aspects of base and nucleotide excision repair in colorectal carcinomas","volume":"18","author":"Slyskova","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S1383-5742(02)00009-1","article-title":"DNA repair\/pro-apoptotic dual-role proteins in five major DNA repair pathways: Fail-safe protection against carcinogenesis","volume":"511","author":"Bernstein","year":"2002","journal-title":"Mutat. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 Blockade in Tumors with Mismatch-Repair Deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/sj.cdd.4400663","article-title":"DNA repair is activated in early stages of p53-induced apoptosis","volume":"7","author":"Geske","year":"2000","journal-title":"Cell Death Differ."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.dnarep.2015.09.003","article-title":"Nucleotide excision repair in humans","volume":"36","author":"Spivak","year":"2015","journal-title":"DNA Repair"},{"key":"ref_30","first-page":"a012609","article-title":"Nucleotide excision repair in eukaryotes","volume":"5","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1093\/mutage\/ger088","article-title":"Differences in nucleotide excision repair capacity between newly diagnosed colorectal cancer patients and healthy controls","volume":"27","author":"Slyskova","year":"2012","journal-title":"Mutagenesis"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/mc.22141","article-title":"Post-treatment recovery of suboptimal DNA repair capacity and gene expression levels in colorectal cancer patients","volume":"54","author":"Slyskova","year":"2015","journal-title":"Mol. Carcinog."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/nrc2342","article-title":"DNA repair pathways as targets for cancer therapy","volume":"8","author":"Helleday","year":"2008","journal-title":"Nat. Rev. Cancer."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nature04885","article-title":"Clarifying the mechanics of DNA strand exchange in meiotic recombination","volume":"442","author":"Neale","year":"2006","journal-title":"Nature"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5864","DOI":"10.1038\/sj.onc.1209874","article-title":"The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability","volume":"25","author":"Gudmundsdottir","year":"2006","journal-title":"Oncogene"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1126\/science.297.5588.1837","article-title":"BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure","volume":"297","author":"Yang","year":"2002","journal-title":"Science"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Kowalczykowski, S.C. (2015). An overview of the molecular mechanisms of recombinational DNA repair. Cold Spring Harb. Perspect. Biol., 7.","DOI":"10.1101\/cshperspect.a016410"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/s41431-017-0021-2","article-title":"Contribution of germline deleterious variants in the RAD51 paralogs to breast and ovarian cancers","volume":"25","author":"Golmard","year":"2017","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/ng.893","article-title":"Germline mutations in RAD51D confer susceptibility to ovarian cancer","volume":"43","author":"Loveday","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1158\/1535-7163.MCT-12-0950","article-title":"RAD51C-deficient cancer cells are highly sensitive to the PARP inhibitor olaparib","volume":"12","author":"Min","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.mrgentox.2013.05.014","article-title":"From DNA damage to chromosome aberrations: Joining the break","volume":"756","author":"Durante","year":"2013","journal-title":"Mutat. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ejca.2017.08.029","article-title":"Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer","volume":"86","author":"Vanderstichele","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/nrm2450","article-title":"ATR: An essential regulator of genome integrity","volume":"9","author":"Cimprich","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrm.2017.48","article-title":"Non-homologous DNA end joining and alternative pathways to double-strand break repair","volume":"18","author":"Chang","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.molcel.2016.11.004","article-title":"Regulation of the DNA damage response by DNA-PKcs inhibitory phosphorylation of ATM","volume":"65","author":"Zhou","year":"2017","journal-title":"Mol. Cell"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.tig.2016.06.007","article-title":"Regulation of single-strand annealing and its role in genome maintenance","volume":"32","author":"Bhargava","year":"2016","journal-title":"Trends Genet."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.dnarep.2015.03.007","article-title":"Cell cycle regulation of human DNA repair and chromatin remodeling genes","volume":"30","author":"Mjelle","year":"2015","journal-title":"DNA Repair"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10689-016-9883-7","article-title":"Hereditary cancer syndromes: Utilizing DNA repair deficiency as therapeutic target","volume":"15","author":"Goyal","year":"2016","journal-title":"Fam. Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0168-9525(99)01930-7","article-title":"Insights into the functions of BRCA1 and BRCA2","volume":"16","author":"Welcsh","year":"2000","journal-title":"Trends Genet."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1101\/gad.14.11.1400","article-title":"Gross chromosomal rearrangements and genetic exchange between nonhomologous chromosomes following BRCA2 inactivation","volume":"14","author":"Yu","year":"2000","journal-title":"Genes Dev."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/00004347-199207000-00003","article-title":"Hereditary ovarian cancer: A clinicopathological study","volume":"11","author":"Bewtra","year":"1992","journal-title":"Int. J. Gynecol. Pathol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/modpathol.2011.211","article-title":"BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma","volume":"25","author":"McAlpine","year":"2012","journal-title":"Mod. Pathol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10689-004-7993-0","article-title":"Peltom\u00e4ki. Lynch syndrome genes","volume":"4","year":"2005","journal-title":"Familial Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"5333","DOI":"10.1038\/onc.2012.584","article-title":"A study of genomic instability in early preneoplastic colonic lesions","volume":"32","author":"Beggs","year":"2013","journal-title":"Oncogene"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.ygyno.2011.02.010","article-title":"Ovarian cancer linked to Lynch syndrome typically presents as early-onset, non-serous epithelial tumors","volume":"121","author":"Ketabi","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1008433","article-title":"ARID1A mutations in endometriosis-associated ovarian carcinomas","volume":"363","author":"Wiegand","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1038\/modpathol.2017.81","article-title":"Molecular-based classification algorithm for endometrial carcinoma categorizes ovarian endometrioid carcinoma into prognostically significant groups","volume":"30","author":"Xu","year":"2017","journal-title":"Mod. Pathol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/his.12934","article-title":"Significant frequency of MSH2\/MSH6 abnormality in ovarian endometrioid carcinoma supports histotype-specific Lynch syndrome screening in ovarian carcinomas","volume":"69","author":"Rambau","year":"2016","journal-title":"Histopathology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e1277308","DOI":"10.1080\/2162402X.2016.1277308","article-title":"Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1\/PDL1 expression","volume":"6","author":"Howitt","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/modpathol.2008.191","article-title":"Intraepithelial T cells and prognosis in ovarian carcinoma: Novel associations with stage, tumor type, and BRCA1 loss","volume":"22","author":"Clarke","year":"2009","journal-title":"Mod. Pathol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Birkbak, N.J., Kochupurakkal, B., Izarzugaza, J.M., Eklund, A.C., Li, Y., Liu, J., Szallasi, Z., Matulonis, U.A., Richardson, A.L., and Iglehart, J.D. (2013). Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0080023"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1158\/1078-0432.CCR-13-0066","article-title":"Non equivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations","volume":"19","author":"George","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.coi.2015.02.004","article-title":"New insights into tumor immunity revealed by the unique genetic and genomic aspects of ovarian cancer","volume":"33","author":"Nelson","year":"2015","journal-title":"Curr. Opin. Immunol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"13587","DOI":"10.18632\/oncotarget.7277","article-title":"Association and prognostic significance of BRCA1\/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1\/PD-L1 in high grade serous ovarian cancer","volume":"7","author":"Strickland","year":"2016","journal-title":"Oncotarget"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1097\/PAS.0000000000000602","article-title":"Mismatch Repair Protein Expression in Clear Cell Carcinoma of the Ovary: Incidence and Morphologic Associations in 109 Cases","volume":"40","author":"Bennett","year":"2016","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/2159-8290.CD-14-0863","article-title":"The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints","volume":"5","author":"Llosa","year":"2015","journal-title":"Cancer Discov."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrclinonc.2010.18","article-title":"Mismatch repair deficient colorectal cancer in the era of personalized treatment","volume":"7","author":"Hewish","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"4719194","DOI":"10.1155\/2017\/4719194","article-title":"Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy","volume":"2017","author":"Viale","year":"2017","journal-title":"Biomed. Res. Int."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Bose, D. (2017). cGAS\/STING Pathway in Cancer: Jekyll and Hyde Story of Cancer Immune Response. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18112456"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"4182","DOI":"10.1074\/jbc.M412566200","article-title":"Epigenetic silencing of the human nucleotide excision repair gene, hHR23B, in interleukin-6-responsive multiple myeloma KAS-6\/1 cells","volume":"280","author":"Peng","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1093\/carcin\/bgp127","article-title":"Cancer-related inflammation, the seventh hallmark of cancer: Links to genetic instability","volume":"30","author":"Colotta","year":"2009","journal-title":"Carcinogenesis"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0090-8258(85)90118-0","article-title":"Clinical pharmacology of intraperitoneal cisplatin","volume":"20","author":"Lopez","year":"1985","journal-title":"Gynecol. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1200\/JCO.1995.13.12.2961","article-title":"Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: A Gynecologic Oncology Group pilot study","volume":"13","author":"Francis","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1586\/14737140.8.7.1135","article-title":"Intraperitoneal chemotherapy: Standard of care for patients with minimal residual stage III ovarian cancer?","volume":"8","author":"Tummala","year":"1987","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.2014.55.9898","article-title":"Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: A gynecologic oncology group study","volume":"33","author":"Tewari","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Jaaback, K., Johnson, N., and Lawrie, T.A. (2016). Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst. Rev., 1.","DOI":"10.1002\/14651858.CD005340.pub4"},{"key":"ref_77","first-page":"1329","article-title":"Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy","volume":"22","author":"Panteix","year":"2002","journal-title":"Anticancer Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3605350","DOI":"10.1155\/2017\/3605350","article-title":"Short-term postoperative cognitive disfunction and inflammatory response in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A pilot study","volume":"2017","author":"Yu","year":"2017","journal-title":"Mediat. Inflamm."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Roth, L., Breuer, E., Gupta, A., Graf, R., Clavien, P., and Lehmann, K. (2018, January 13\u201316). The impact of HIPEC on anticancer immune response. Proceedings of the ESMO Immuno-Oncology Congress 2018, Geneva, Switzerland.","DOI":"10.1093\/annonc\/mdy487.036"},{"key":"ref_80","first-page":"310","article-title":"Time course of cytokines, hemodynamic and metabolic parameters during hyperthermic intraperitoneal chemotherapy","volume":"82","author":"Coccolini","year":"2016","journal-title":"Minerva Anestesiol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/toxsci\/kfu029","article-title":"Cisplatin plus sodium arsenite and hyperthermia induces pseudo-G1 associated apoptotic cell death in ovarian cancer cells","volume":"139","author":"Muenyi","year":"2014","journal-title":"Toxicol. Sci."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3389\/fphar.2016.00376","article-title":"Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone","volume":"7","author":"Lolli","year":"2016","journal-title":"Front. Pharmacol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1245\/s10434-014-4097-4","article-title":"High neutrophil-to-lymphocyte ratio persistent during first-line chemotherapy predicts poor clinical outcome in patients with advanced urothelial cancer","volume":"22","author":"Rossi","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"54564","DOI":"10.18632\/oncotarget.10515","article-title":"Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib","volume":"7","author":"Lolli","year":"2016","journal-title":"Oncotarget"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"33210","DOI":"10.18632\/oncotarget.8901","article-title":"Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer","volume":"7","author":"Passardi","year":"2016","journal-title":"Oncotarget"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"46414","DOI":"10.18632\/oncotarget.16793","article-title":"Preoperative neutrophil-to-lymphocyte ratio is a predictor of survival of epithelial ovarian cancer: A systematic review and meta-analysis of observational studies","volume":"8","author":"Yang","year":"2017","journal-title":"Oncotarget"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1159\/000475911","article-title":"Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Ovarian Cancer: A Systematic Review and Meta-Analysis of Observational Studies","volume":"41","author":"Huang","year":"2017","journal-title":"Cell. Physiol. Biochem."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s11523-018-0574-1","article-title":"Inflammatory indexes as predictive of prognosis and bevacizumab efficacy in ovarian cancer. A multicentre retrospective analysis from the MITO group (MITO 24)","volume":"13","author":"Farolfi","year":"2018","journal-title":"Target Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00280-004-0779-0","article-title":"Hyperthermia modifies pharmacokinetics and tissue distribution of intraperitoneal melphalan in a rat model","volume":"54","author":"Glehen","year":"2004","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_90","unstructured":"Chabner, B.A., and Collins, J.M. (1990). Cancer Chemotherapy: Principles and Practice, Lippincott Company."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e1060392","DOI":"10.1080\/2162402X.2015.1060392","article-title":"Hyperthermic intra-peritoneal chemotherapy and anticancer immune response","volume":"5","author":"Zunino","year":"2016","journal-title":"Oncoimmunology"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/onc.2015.82","article-title":"Hyperthermic intraperitoneal chemotherapy leads to an anticancer immune response via exposure of cell surface heat shock protein 90","volume":"35","author":"Zunino","year":"2016","journal-title":"Oncogene"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: A single-arm, multicentre, phase 2 trial","volume":"387","author":"Balar","year":"2016","journal-title":"Lancet"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41591-018-0012-z","article-title":"ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade","volume":"24","author":"Shen","year":"2018","journal-title":"Nat. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1093\/annonc\/mds178","article-title":"Deterioration in quality of life (QoL) in patients with malignant ascites: Results from a phase II\/III study comparing paracentesis plus catumaxomab with paracentesis alone","volume":"23","author":"Wimberger","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1002\/ijc.25423","article-title":"The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II\/III trial","volume":"127","author":"Heiss","year":"2010","journal-title":"Int. J. Cancer"},{"key":"ref_99","first-page":"4272","article-title":"The clinical effects of dendritic cell vaccines combined with cytokine-induced killer cells intraperitoneal injected on patients with malignant ascites","volume":"7","author":"Ai","year":"2014","journal-title":"Int. J. Clin. Exp. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/cgt.2016.49","article-title":"Intraperitoneal immunotherapy: Historical perspectives and modern therapy","volume":"23","author":"Morano","year":"2016","journal-title":"Cancer Gene Ther."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/cgt.2016.14","article-title":"Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery","volume":"23","author":"Katz","year":"2016","journal-title":"Cancer Gene Ther."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e994446","DOI":"10.4161\/2162402X.2014.994446","article-title":"IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo","volume":"4","author":"Koneru","year":"2015","journal-title":"Oncoimmunology"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Hong, H., Brown, C.E., Ostberg, J.R., Priceman, S.J., Chang, W.C., Weng, L., Lin, P., Wakabayashi, M.T., Jensen, M.C., and Forman, S.J. (2016). Cell Adhesion Molecule-Specific Chimeric Antigen Receptor-Redirected Human T Cells Exhibit Specific and Efficient Antitumor Activity against Human Ovarian Cancer in Mice. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0146885"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.clim.2009.08.007","article-title":"Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival","volume":"133","author":"Dobrzanski","year":"2009","journal-title":"Clin. Immunol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/10\/2569\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:55:01Z","timestamp":1760187301000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/10\/2569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,25]]},"references-count":104,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2019,5]]}},"alternative-id":["ijms20102569"],"URL":"https:\/\/doi.org\/10.3390\/ijms20102569","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,25]]}}}